Acurx Pharmaceuticals Inc. held its annual meeting on July 17, 2025. During the meeting, stockholders elected Carl V. Sailer and Thomas Harrison as Class I directors. The appointment of CohnReznick LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. The issuance of shares of common stock underlying Series F Warrants and Wainwright Warrants was approved. The issuance of shares to Lincoln Park Capital Fund, LLC was also approved. An amendment to increase the number of shares available under the 2021 Equity Incentive Plan was approved.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Acurx Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-068659), on July 17, 2025, and is solely responsible for the information contained therein.